Navigation Links
Nephros Reports First Quarter 2012 Financial Results
Date:5/15/2012

obtain appropriate or necessary regulatory approvals to achieve our business plan;
  • products that appeared promising to us in research or clinical trials may not demonstrate anticipated efficacy, safety or cost savings in subsequent pre-clinical or clinical trials;
  • we may encounter problems with our suppliers and manufacturers;
  • we may encounter unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures;
  • HDF therapy may not be accepted in the United States and/or our technology and products may not be accepted in current or future target markets, which could lead to failure to achieve market penetration of our products;
  • we may not be able to effectively market products, including our HDF system
  • we may not be able to sell our chronic renal failure therapy or water filtration products at competitive prices or profitably;
  • we may not be able to secure or enforce adequate legal protection, including patent protection, for our products; and
  • we may not be able to achieve sales growth in key geographic markets.
  • More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements, including the forward-looking statements in this press release, is set forth in our filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and our other periodic reports filed with the SEC. We urge investors and security holders to read those documents free of charge at the SEC's web site at www.sec.gov. We do not undertake to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.NEPHROS, INC. AND SUBSIDIARYCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)March 31, 2012December 31, 2011(Unaudited)(Audited)Assets:
    '/>"/>

    SOURCE Nephros, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
    2. Nephros Reports 2009 Third Quarter Financial Results
    3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
    4. Nephros Signs Development Agreement with STERIS
    5. Nephros Reports 2010 First Quarter Financial Results
    6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
    7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
    8. Nephros Reports 2010 Second Quarter Financial Results
    9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
    10. Nephros Reports 2010 Third Quarter Financial Results
    11. Nephros Rights Offering Registration Statement Declared Effective
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/30/2015)...  EP Global Communications, Inc. (OTC-PINK: EPGL) In a ... negotiations with CooperVision, Inc. at $1.1 billion for ... technologies. As previously disclosed publicly, CooperVision, Inc. and ... lens technologies, which has led to several new ... experts that just one of these newly developed ...
    (Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... addition of the "Computer Aided Detection (CAD) ... their offering. Annual estimates and forecasts ... Also, a six-year historic analysis is provided for ... from primary and secondary research. Company profiles are ...
    (Date:3/30/2015)... YORK , March 30, 2015  Check-Cap Ltd. ... company focused on the development of a preparation-free ingestible ... for colorectal cancer, announced today that its CEO, Guy ... March 31, 2015 trading day.  Neev and Check-Cap will ... commemorate the company,s initial public offering and simultaneous private ...
    Breaking Medicine Technology:CooperVision, Inc. Seeks Intermediary as EP Global Communications, Inc., Opens Negotiations at $1.1B 2CooperVision, Inc. Seeks Intermediary as EP Global Communications, Inc., Opens Negotiations at $1.1B 3Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 2Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 3Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 4Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 2Check-Cap to Celebrate Initial Public Offering with NASDAQ Closing Bell Ceremony on March 31, 2015 3
    (Date:3/30/2015)... March 30, 2015 Recently, 10 Best ... Water Awards, with the top three winners being Fiji water, ... the company’s website, along with other informative information about water. ... water, spring water, mineral water and sparkling water are among ... of the top exotic water brands highlighted on the ...
    (Date:3/30/2015)... Pa. (PRWEB) March 30, 2015 ... the Halal certification for all current Epax® Ultra ... facility in Ålesund, Norway. The certification ensures the ... comply with the Islamic religious regulations for Halal. ... step in FMC’s efforts to further advance its ...
    (Date:3/30/2015)... 2015 Slidezilla, an app from the ... app that innovates the fun and simplicity of photo ... animated photo slideshows and then instantly share them across ... "We wanted to create a slideshow app where users ... many fun options to personalize them. You can choose ...
    (Date:3/30/2015)... (PRWEB) March 30, 2015 V/NO (Virtually No ... a convenient flute for opening/closing and for reuse. Consumers simply ... the go. Health-conscious New Yorkers, professionals, and basically anyone can ... yet delicious to kick back socially or pair with meals ... “ V/NO is dealcoholized wine and that means Napa ...
    (Date:3/30/2015)... California (PRWEB) March 30, 2015 ... as radioactive isotopes, radiopharmaceuticals are used as tracers ... global market for radiopharmaceuticals is driven by the ... in the field of cardiology, neurology, pulmonology, and ... by the well-established use of radioisotopes in diagnostic ...
    Breaking Medicine News(10 mins):Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 4
    ... Oct. 25 Reaching out to a key,demographic, Sen. ... by Women,s Voices for Change, the New York-based group ... women,s health and well-being,in the menopause years. The interview ... ., "Right now, the uninsured are carrying a ...
    ... BOSTON October 25, 2007 Shire plc ... specialty biopharmaceutical company, today announced the results of ... Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ... with once-daily VYVANSE (lisdexamfetamine dimesylate), the first prodrug ...
    ... as HIV treatment improved and as HIV-related public health ... and seek care, that HIV-infected patients would seek care ... actually sicker when they begin therapy. The study is ... Diseases, currently available online. , The study, carried out ...
    ... Action allows Novavax to focus on its vaccine ... Oct. 25 Novavax, Inc.,(Nasdaq: NVAX ) ... Inc. to,terminate its manufacturing supply agreement for Estrasorb. ... Inc. (recently acquired by,Allergan, Inc.) in 2006 and ...
    ... The wildfires ravaging large,swathes of Southern California are ... billion, making them among the most expensive in ... Solutions (RMS),the world,s leading provider of products and ... to spread in this ongoing situation,losses are expected ...
    ... population is infected with Mycobacterium tuberculosis, the bacterium ... people died of the disease in 2005. Currently, ... regimen over a six- to nine-month period. This ... doses, which has given rise to drug-resistant strains ...
    Cached Medicine News:Health News:VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment 2Health News:HIV patients sicker when seeking care than in the past 2Health News:Novavax and Allergan Terminate Manufacturing Supply Agreement for Estrasorb 2Health News:Novavax and Allergan Terminate Manufacturing Supply Agreement for Estrasorb 3Health News:California Wildfires Could Cost Insurers Over $1.5BN, Says RMS 2
    ... Virion\Serions comprehensive line of ELISA Classic ... bacterial, viral, and fungal pathogens with rapid, ... and IgA antibodies. All of the ELISA ... produced in their own laboratories under the ...
    ... Osiris is a ... management software and an ... the inhibition zone size ... Osiris offers built-in expertise ...
    ... Medical Records for small and large multi-specialty ... check-in to check-out. Review the complete Patient ... to allergies, labs and charts all by ... patient records immediately. Communicate electronically with the ...
    ... Health Record streamlines patient information management ... A flexible and easily customizable solution, ... financial benefits. HealthMatics EHR organizes communication ... and with outside practitioners. It also ...
    Medicine Products: